FIELD: biotechnology.
SUBSTANCE: invention relates to the recombinant production of an antibody or its antigen-binding fragment that binds GITR, and can be used in medicine for tumor therapy.
EFFECT: invention makes it possible to obtain an antibody or its antigen-binding fragment capable of specifically binding GITR and acting as a human GITR agonist with improved activity.
110 cl, 15 dwg, 14 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY | 2012 |
|
RU2715642C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
| ENGINEERED pH-DEPENDENT ANTI-CD3 ANTIBODIES, AS WELL AS METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2832079C2 |
| ANTI-IL31 ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2835543C1 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
